Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
A phase 3 trial of Savolitinib, Durvalumab, Sunitinib in renal cell carcinoma, run by AstraZeneca, active and no longer recruiting.
Overview
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC is a phase 3 interventional study registered as NCT05043090 by AstraZeneca, with 148 participants enrolled, started 2021-10-28 and due to reach its primary completion in 2025-12-31. Interventions recorded: savolitinib, durvalumab, sunitinib. Conditions listed: Papillary Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialSavolitinib vs. Sunitinib in MET-driven PRCC.
Shares Savolitinib, Sunitinib, Renal cell carcinoma, AstraZeneca.
- TrialSavolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
Shares Savolitinib, Durvalumab, AstraZeneca.
- TrialA Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC
Shares Savolitinib, AstraZeneca.
- TrialA Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
Shares Durvalumab, AstraZeneca.
- TrialDurvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
Shares Durvalumab, AstraZeneca.
- TrialA Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment
Shares Durvalumab, AstraZeneca.
- TrialOsimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
Shares Savolitinib, AstraZeneca.
- TrialPhase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
Shares Savolitinib, Durvalumab, AstraZeneca.